



NOVAGALI P H A R M A

Availability of the 2011 half-year financial report

Evry (France), August 31st, 2011: Novagali Pharma, a pharmaceutical company that develops and markets innovative ophthalmic products, informs its shareholders and the financial community that its 2011 half-year report is now available on the Group's website www.novagali.com / Investors and Media section.

[About NOVAGALI Pharma \(www.novagali.com\)](http://www.novagali.com)

Founded in 2000, Novagali Pharma SA is a pharmaceutical company that develops ophthalmic innovative products for all segments of the eye. Thanks to its three proprietary technology platforms, the Company has an advanced portfolio of highly innovative products, one of which is already on sale and two of which are undergoing phase III clinical trials.

In 2009, Frost & Sullivan recognised Novagali with the Award for Industry Innovation & Advancement of the Year, for its proprietary emulsion technology platforms, and Siemens awarded the company the "Health Award" *Grand Prix de l'Innovation* for Novasorb[®].

Novagali Pharma carried out a successful IPO in July 2010 enabling the Company to raise €22 million.

Novagali Pharma is listed on NYSE Euronext Paris - Compartment C. ISIN code: FR0010915553 - Ticker: NOVA.

This press release contains forward-looking statements. Although Novagali Pharma considers these statements to be based on reasonable assumptions, they could be affected by risks and uncertainties causing actual results to differ significantly from these forward-looking statements. For details of the risks and uncertainties that could potentially affect Novagali Pharma's results, financial situation, performances or achievements and thus result in a variation in these figures compared to the forward-looking statements contained in this document, please refer to the Risk Factors sections of the Document de Référence (annual report) registered with the French Autorité des Marchés Financiers ("AMF") under n° R. 11-021 on April 29th, 2011 and of the half-year financial report filed today with the AMF. These documents are available on the AMF (<http://www.amf-france.org>) and Novagali Pharma (www.novagali.com) websites.

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in Novagali Pharma in any country.



Next press release
Revenue for the 3rd quarter of 2011: November 15th, 2011
(after market)

[Contacts](#)

Novagali
Geneviève Garrigos
VP RH & Communication
Tel: +33 (0)6 65 54 60 19

NewCap.
Financial communication
Axelle Vuillermet / Emmanuel Huynh
Tel: +33 (0)1 44 71 94 93
Email: novagali@newcap.fr

Novagali Pharma is listed on NYSE Euronext Paris - Compartment C
ISIN code: FR0010915553 - Ticker: NOVA